TherapeuticsMD (NASDAQ:TXMD) Coverage Initiated at StockNews.com

Posted by Oscar Bower on Aug 1st, 2024

Stock analysts at StockNews.com began coverage on shares of TherapeuticsMD (NASDAQ:TXMD – Get Free Report) in a note issued to investors on Tuesday. The firm set a “hold” rating on the stock.

TherapeuticsMD Stock Performance

TXMD stock opened at $1.75 on Tuesday. TherapeuticsMD has a 12-month low of $1.43 and a 12-month high of $4.35. The company’s fifty day simple moving average is $1.89 and its 200 day simple moving average is $2.09.

TherapeuticsMD (NASDAQ:TXMD – Get Free Report) last released its quarterly earnings data on Friday, May 10th. The company reported ($0.07) earnings per share (EPS) for the quarter. The firm had revenue of $0.31 million for the quarter.

Hedge Funds Weigh In On TherapeuticsMD

A hedge fund recently bought a new stake in TherapeuticsMD stock. Prosperity Consulting Group LLC acquired a new position in shares of TherapeuticsMD, Inc. (NASDAQ:TXMD – Free Report) during the first quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor acquired 24,500 shares of the company’s stock, valued at approximately $56,000. Prosperity Consulting Group LLC owned approximately 0.21% of TherapeuticsMD at the end of the most recent reporting period. 30.74% of the stock is currently owned by hedge funds and other institutional investors.

About TherapeuticsMD

(Get Free Report)

TherapeuticsMD, Inc operates as a pharmaceutical royalty company in the United States. It has a license agreement with Mayne Pharma to commercialize the IMVEXXY, BIJUVA, and ANNOVERA prescription prenatal vitamin products sold under the BocaGreenMD and vitaMedMD brand names. The company sells its prescription pharmaceutical products and prenatal vitamin products through wholesale distributors and retail pharmacy distributors.